AstraZeneca, shared a post on LinkedIn:
“We have a bold ambition in oncology – to one day eliminate cancer as a cause of death.
Our Oncology R&D strategy supports our ambition to transform outcomes for patients by attacking cancer from multiple angles, treating earlier and smarter, and leading with transformational technologies.
Susan Galbraith, Executive Vice President, Oncology Haematology R&D, explains how we’re driving momentum and aiming to shape the future of cancer care.”
Other articles featuring Susan Galbraith on OncoDaily.